top of page
OPADE  PROJECT  HORIZON-HLTH-2022-TOOL-11-01  HORIZON Proj#  101095436

Distributive Section

Mail Box 2

Contact List

7865 - Copia.jpg

Annual Meeting 2024 Doc Rep

cartoleria

OPADE Proposed Project

cartoleria
cartoleria

OPADE Extimated Budget

                                                Acronym OPADE
Proposal title Optimise and predict antidepressant efficacy for patient with major depressive disorders using multi-omics analysis and AI-predictive tool
Note that for technical reasons, the following characters are not accepted in the Duration in months 54 Arg.1 Biochemistry and molecular biology Arg.2 Other clinical medicine on subjects with major depression disorder, AI-predictive tool, anti-depressant efficacy, gut-brain-axis
Abstract *
280M of people worldwide suffers from major depressive disorders (MDD). Although a well-populated therapeutic landscape of antidepre280M of people worldwide suffers from major depressive disorders (MDD). Although a well-populated therapeutic landscape of anti-depressants, the number of patients in remission is particularly low with not more than 6% of the patients who benefit from thecurrent therapeutic journey.
OPADE objective is to identify key biomarkers that support the decision-making process of the healthcare providers. The project focuses on the microbiota – brain -axis which plays a major role in mental health and in particular MDD. Through clinical investigations, the consortium partners will study the combination between genetics, epigenetics, microbiome and inflammatory networks to:
- Establish patient profiles to predict and optimise the efficacy of the antidepressants prescribed with an increase in the remission rate and reduction of impairment of real-life functioning,
- Establish the possible correlation between neuroinflammatory indices, target indicators of the microbiome, metabolomics, immune-profile linked, epigenomic, enzymatic algorithms,
- Evaluate molecular and non-molecular biomarkers that may represent predictive indices of recurrence
- Discover new molecular targets for a personalised approach,
- Improve the diagnostic accuracy for primary prevention,
- Evaluate retrospectively, using accurate anamnesis, the onset of depressive symptoms in adolescence.
- Establish how much and to what extent do blood biomarkers correlate with other specific biomarkers
350 patients between 14 and 50 years will be recruited in 6 EU and international countries for 24 months. Real-time EEG and patient cognitive assessment will be collected with blood, stool and saliva samples. Results and analysis will be used to train the AI / ML predictive tool, the main outcome of the project. A patient empowerment tool will be deployed over the project duration.

Interactive Section

meeting

OPADE Partners File file exchange

Sigma Horizon 21-27 System

bottom of page